| Drug ID: | Drug86 |
|---|---|
| Drug Name: | Vitamin K |
| CID: | 5280483 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT01839214 |
| Molecular Formula: | C31H46O2 |
| Molecular Weight: | 450.7 g/mol |
| Isomeric SMILES: | CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCCC(C)CCCC(C)CCCC(C)C |
| Synonyms: | VITAMIN K; 12001-79-5; 81818-54-4; Kephton; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; Vitamin K1(20); .alpha.-Phylloquinone; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 3-methyl-2-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)naphthalene-1,4-dione |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt716 | 5280483 | Vitamin K | 2147 | F2 | Homo sapiens (human) | Cofactor | |
| dt717 | 5280483 | Vitamin K | 59 | ACTA2 | Rattus norvegicus (Norway rat) | 23117658 | [warfarin co-treated with vitamin K co-treated with quercetin] results in increased expression of ACTA2 mRNA |
| dt718 | 5280483 | Vitamin K | 105387 | Akr1c14 | Rattus norvegicus (Norway rat) | 16844298 | Vitamin K affects the expression of AKR1C14 mRNA |
| dt719 | 5280483 | Vitamin K | 348 | APOE | Homo sapiens (human) | 15952022 | APOE protein affects the abundance of vitamin K |
| dt720 | 5280483 | Vitamin K | 348 | APOE | Homo sapiens (human) | 16847429 | APOE protein affects the uptake of vitamin K |
| dt721 | 5280483 | Vitamin K | 8313 | AXIN2 | Rattus norvegicus (Norway rat) | 23117658 | Quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of AXIN2 mrna]|[warfarin co-treated with vitamin K] results in increased expression of AXIN2 mRNA |
| dt722 | 5280483 | Vitamin K | 558 | AXL | Homo sapiens (human) | 26206560 | Vitamin K results in increased expression of AXL protein modified form|vitamin K inhibits the reaction [warfarin results in decreased expression of AXL protein modified form] |
| dt723 | 5280483 | Vitamin K | 632 | BGLAP | Rattus norvegicus (Norway rat) | 23117658 | [warfarin co-treated with vitamin K] results in increased expression of BGLAP mrna|quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of BGLAP mrna] |
| dt724 | 5280483 | Vitamin K | 847 | CAT | Rattus norvegicus (Norway rat) | 33063951 | Vitamin K inhibits the reaction [9,10-dimethyl-1,2-benzanthracene results in decreased activity of CAT protein] |
| dt725 | 5280483 | Vitamin K | 595 | CCND1 | Rattus norvegicus (Norway rat) | 23117658 | Quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of CCND1 mrna]|[warfarin co-treated with vitamin K] results in increased expression of CCND1 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03358706 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | PHASE1 | TERMINATED | Janssen Research & Development, LLC | Crohn Disease|Ulcerative Colitis | DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… | Details |
| JPRN-UMIN000006915 | Randomized controlled trial for the management of osteoporosis in inflammatory bowel disease - The management of osteoporosis in inflammatory bowel disease | Not Available | Not Recruiting | Department of Gastroenterology, Osaka University Graduate School of Medicine | Inflammatory bowel disease | Bisphosphonate (risedoronate) Vitamin K (menatetr… | Details |
| NCT04624230 | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | PHASE3 | RECRUITING | Pfizer | Ulcerative Colitis | DRUG: tofacitinib | Details |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) | PHASE3 | RECRUITING | Merck Sharp & Dohme LLC | Crohn Disease|Colitis, Ulcerative | DRUG: Tulisokibart|DRUG: Placebo to tulisokibart | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT05180279 | The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis | None | COMPLETED | Rush University Medical Center | Ulcerative Colitis | BEHAVIORAL: 7-day sleep lab | Details |
| NCT03773952 | Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients | PHASE2 | COMPLETED | Palobiofarma SL | Ulcerative Colitis | DRUG: PBF-677|DRUG: Placebo oral capsule | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT02762500 | An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis | PHASE2 | COMPLETED | Lycera Corp. | Colitis, Ulcerative | DRUG: LYC-30937-EC|DRUG: Placebo | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | PHASE2 | ACTIVE_NOT_RECRUITING | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ulcerative Colitis | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… | Details |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… | Details |
| NCT05019742 | Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis | PHASE2 | RECRUITING | Shanghai Pharma Biotherapeutics USA Inc. | Ulcerative Colitis | DRUG: SPH3127|DRUG: Placebo | Details |
| NCT01759056 | Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis | PHASE1 | COMPLETED | Avaxia Biologics, Incorporated | Ulcerative Colitis | DRUG: AVX 470|DRUG: Placebo | Details |
| NCT03893565 | Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis | PHASE2 | TERMINATED | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK2831781 - Double Blind Phase|DRUG: Place… | Details |
| NCT06049017 | A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: JNJ-77242113|DRUG: Placebo | Details |
| NCT01771224 | Effect of FAn-7 in UC Activity | EARLY_PHASE1 | UNKNOWN | National Institute of Medical Sciences and Nutrition, Salvador Zubiran | Inflammatory Bowel Disease|Ulcerative Colitis | DIETARY_SUPPLEMENT: Palmitoleic acid | Details |
| NCT05784246 | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis | PHASE3 | RECRUITING | Eli Lilly and Company | Ulcerative Colitis | DRUG: Mirikizumab IV|DRUG: Mirikizumab SC | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Maternal and Neonatal Hemorrhage From Vitamin K Deficiency in the Setting of Cr…
PMID: 40048733
Year: 2025
Relationship Type:
Association
Score: 6.5
BACKGROUND: Patients with inflammatory bowel disease, particularly Crohn disease (CD), are at increased risk of fat malabsorption and fat-soluble vit…
Pregnane X Receptor Signaling Pathway and Vitamin K: Molecular Mechanisms and C…
PMID: 38667296
Year: 2024
Relationship Type:
Treatment
Score: 6.5
This review explores the likely clinical impact of Pregnane X Receptor (PXR) activation by vitamin K on human health. PXR, initially recognized as a …
Low Vitamin K and Vitamin D Dietary Intake in Patients with Inflammatory Bowel …
PMID: 37049518
Year: 2023
Relationship Type:
Association
Score: 6.5
The inadequate dietary intake of Vitamin D and Vitamin K is an easily reversible factor favoring IBD-associated bone loss, but data on Vitamin K are …
Ameliorating Effects of Vitamin K2 on Dextran Sulfate Sodium-Induced Ulcerative…
PMID: 36769323
Year: 2023
Relationship Type:
Mechanism
Score: 6.5
Ulcerative colitis (UC) is a chronic recurrent inflammatory illness of the gastrointestinal system. The purpose of this study was to explore the alle…
Role of Vitamin K in Intestinal Health
PMID: 35069573
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Intestinal diseases, such as inflammatory bowel diseases (IBDs) and colorectal cancer (CRC) generally characterized by clinical symptoms, including m…
The Impact of Vitamin K2 (Menaquionones) in Children's Health and Diseases: A R…
PMID: 35053702
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Vitamin K2 activates vitamin K-dependent proteins that support many biological functions, such as bone mineralization, the inhibition of vascular sti…
[Vitamin K2 influences several diseases]
PMID: 26321585
Year: 2015
Relationship Type:
Clinical Trial
Score: 6.3
In this paper we discuss the evidence of vitamin K2 deficiency which is a factor in several chronic diseases like diabetes, osteoporosis, cancer, inf…
Vitamin K deficiency bleeding leading to the diagnosis of Crohn's disease
PMID: 25117110
Year: 2014
Relationship Type:
Association
Score: 6.3
We report the case of a 45 year old man who came to Emergency Room of Polyclinic for sudden onset of localized ecchymosis and widespread hematomas. H…
Early vitamin K deficiency bleeding in a neonate associated with maternal Crohn…
PMID: 25073494
Year: 2014
Relationship Type:
Association
Score: 6.3
We report herein a case of early vitamin K deficiency bleeding (VKDB) in a neonate associated with maternal Crohn's disease. A female neonate was bor…